AstraZeneca Can't Dodge Nexium Antitrust Claims

Law360, New York (September 12, 2013, 9:38 PM EDT) -- A Massachusetts federal judge Wednesday largely kept intact multidistrict litigation brought by direct- and third-party purchasers that allege AstraZeneca PLC and several generic-drug makers violated antitrust laws by entering into agreements to delay entry of a generic version of AstraZeneca's heartburn drug Nexium.

U.S. District Judge William G. Young denied multiple attempts by AstraZeneca, Ranbaxy Inc., Teva Pharmaceutical Industries, Ltd. and Dr. Reddy’s Laboratories Ltd. to dismiss the entirety of federal and state antitrust claims from the litigation. Judge Young rejected the companies' collective attempt to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.